Oncology

The HexaBody technology builds on natural antibody biology and enhances the assembly of antibody hexamers (clusters of six) after target binding at the cell surface. This results in enhancement of immune effector functions including complement-mediated killing (complement-dependent cytotoxicity (CDC)). The HexaBody technology can transform antibodies with limited or absent CDC into potent, cytotoxic antibodies.

Antibody technology platform, hexamerization, complement, crosslinking, potency, affinity